The VenaSeal Spectrum Program is:

• Comprised of three distinct studies.
• Designed to expand evidence across the spectrum of superficial venous disease.
• Designed with novel, patient-centered endpoints.

The VenaSeal Spectrum Program is the largest post-market clinical study of the VenaSeal™ Closure System compared to the current standards of care.

VenaSeal™ Closure System
Cyanoacrylate Closure

In two randomized controlled studies for the CEAP 2-5 population, the outcomes of VenaSeal treatments are compared to either endothermal ablation (ETA) or surgical stripping (SS). In a separate single-arm study for the CEAP 6 population, the outcomes of the VenaSeal treatment are prospectively assessed in the treatment of active venous leg ulcer (VLU) patients.
Primary endpoints

Venous Treatment Satisfaction Questionnaire (VenousTSQ)
- New, novel patient-reported outcome measure
- Measures patient treatment satisfaction
- Created specifically for superficial venous disease treatment across the CEAP spectrum

Elimination of truncal reflux
- Patient-centered primary endpoint

Time to ulcer healing
- Patient-centered primary endpoint in the VenaSeal Spectrum Venous Leg Ulcer (VLU) study

See the device manual for detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu

©2023 Medtronic. All rights reserved. Medtronic, Medtronic logo, and Engineering the extraordinary are trademarks of Medtronic. ™ Third-party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.

UC202312661-venaseal-spectrum-study-infosheet-en-we-8990729